Overview

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

Status:
Completed

Trial end date:
2019-04-29

Target enrollment:

Participant gender:

Summary

This is an open-label 2-part Phase I study in patients with advanced solid tumours. Part A of the study (mandatory) will assess the effect of olaparib on the pharmacokinetics (PK) of anastrozole, letrozole and tamoxifen and vice versa; Part B will allow patients (if eligible) continued access to olaparib after the PK phase and will provide additional safety data.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Anastrozole
Letrozole
Olaparib
Tamoxifen